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Mixing 
Mixing of the bioreactor broth is needed for effective 
gas blending and to maintain optimum conditions 
throughout the solution, which are essential for the 
survival and growth of yeast. The mixing team 
designed a bioreactor system which ensured that 
these requirements were met in order to maximize 
yeast growth. A series of experiments were carried 
out to determine the dimensions and design of the 
bioreactor, its baffle system and impeller. The ideal 
stirrer speed was also calculated. The data 
obtained was used to construct a baffle system and 
to design the impellers and bioreactor. This 
bioreactor was used in a 24 hour trial run. 
Introduction 
Tuberculosis is an infectious disease caused 
by different strains of Mycobacterium 
Tuberculosis, and transmitted by respiratory 
fluids generated through coughing, 
sneezing, etc. 
 
To this day, the only TB vaccine available is 
the BCG; however, it has various limitations. 
It is only effective on the young, and 
cannot be given to new-borns, who are at 
risk of infection. Additionally, as it is a live 
vaccine, an individual with a suppressed 
immune system cannot be vaccinated, 
e.g. HIV + individuals. 
  
 
Instrumentation 
The aim for this series of experiments was to design a 4 
electrode impedance probe that could be used to 
determine the optimum time at which the yeast 
should be collected. Experimentation of different 
electrode positions was carried out. Investigations 
into the AC frequency and the background solution 
enabled determination of when to remove the 
yeast. Unfortunately it quickly became clear that 
the electrical properties of the mixture were subject 
to many different conditions. Furthermore, the 
readings were low in precision; thus errors were 
found in the final results due to minute changes in 
conditions. 
 
Medium Broth 
The aim for this series of experiments was to determine 
the optimum conditions to maximize yeast growth. 
Various YEPD solutions of different sugar 
concentrations were prepared; initially a pH buffer 
was not added. A pre-cultured yeast inoculum was 
added to all the vessels and the fluid flow was 
turbulent at all times. At set time intervals, samples 
were taken from the fermentation broth and the 
absorbance recorded using a spectrophotometer. 
The results showed that the optimum sugar 
concentration for maximum yeast growth was 10% 
glucose, and the buffer was needed to maintain the 
pH. 
24 hr Run – Bioreactor results 
Purpose 
Undergraduate research into a new Tuberculosis 
vaccine for those living in endemic parts of sub-
Saharan Africa through the design of sub-unit 
vaccine process engineering and manufacturing 
systems. We intend to produce a subunit vaccine, 
containing antigenic proteins: RV0097 and 
FABG4.  
 
Method Summary 
Isolate the gene for proteins RV0097 and FABG4 
from the TB bacteria. 
 
Extract a plasmid DNA from a bacterium and cut 
it open with restriction enzymes 
Insert the isolated protein-producing gene into 
the bacterial plasmid vector, forming 
recombinant DNA and introduce this to a yeast 
cell. 
 
Grow the yeast cells in a bioreactor. 
The desired proteins are produced inside the 
yeast and need to be isolated via centrifugation 
and filtration. 
 
Chromatography and other methods are 
required to purify our product. 
To increase stability, the vaccine must be 
formulated. 
 
Mixing Vessel Design: 
Diameter of impeller: 40mm 
Height of impeller from vessel bottom: 25mm 
Impeller shape: Triangular Prism 
Impeller Cross Section Side: 10mm 
Vessel diameter: 65mm 
Stirring power: 0.85W 
Temperature: 30-350C 
 
pH: 4-5 with the use of a phosphate buffer 
 
Impeller speed: 600rpm 
 
Media: YEPD (Yeast Extract Peptone 
Dextrose) 
 
 Sugar Concentration: 10% 
 
Water grade: Grade 1 water certified by 
ACTM. 
 
rMedium broth - The results from 
the 24 hour run showed that 
room temperature with a 
10% glucose concentration 
was sufficient for the yeast 
inoculum to produce 0.06g 
per ml.  
Instrumentation – The 
Experiment results were 
inconclusive. Ideally, another  
controlled experiment needs 
to be carried out.  
 
Design Specification 
Marketing – Scale Up 
Place: Sub-Saharan Africa 
Target for 1st year of production:  
33.6 million newborns 
Vaccine Dose: 33.6 million shots 
(15µg) 
Budget: £50-150 million (based on 
£1.50-4.50 per dose) 
 
Biochemical Engineering: Yash Mishra, Katrina Galve, Georgina Hunter Chemical  Engineering: Chibi Anaduaka, Louise Roberts, Marouf Malik Medical Physics: Ashkan Pakzad, David Adams 
Scaling up the production of the vaccine to an industrial scale involved the use of 
results from the 24 hour run, and considering costs and efficiency also. 0.066 grams of 
wet cell weight per ml of solution were produced in the lab solution, and so it was 
assumed that this result could be extrapolated.  
Relevant figures were researched, including sub-Saharan Africa’s birth rate (38.36 per 
1000) [1], sub-Saharan Africa’s population (874,841,049) [1], protein weight per vaccine 
dose (50 micrograms) [2], number of doses required per patient (three per patient) [3] 
and dose volume (0.25ml) [4].  
It was determined that to produce three doses per patient for 33,558,900 new-borns in a 
year, with each dose containing 50 micrograms of proteins, the bioreactor would need 
to contain approximately 7,600 litres of broth. Allowing for space for foam formation 
and air, it was decided that a 10,000 litre bioreactor would be suitable. This would need 
to operate for 16 weeks to provide the required amount of proteins.  
The lab experiments were performed using a 250ml beaker with a height to diameter 
ratio of 1.159. Maintaining this ratio with a 10,000 litre bioreactor gave a diameter of 
2.223m and a height of 2.576m.  
It was decided that the impeller type would be a standard six-blade Rushton turbine. It 
was calculated that the power consumption of the entire facility was 20kW, 15kW of 
which is required by the bioreactor control systems. 
[1] – http://www.tradingeconomics.com/sub-saharan-africa/population-total-wb-data.html 
[2] – http://www.rxlist.com/typhim-drug.htm 
[3] – http://www.patient.co.uk/health/Hepatitis-B-Immunisation 
[4] – http://www.ncbi.nlm.nih.gov/pubmed/9202817 
 
